DermTech, Inc. provided revenue guidance for the first quarter and full year of 2022. Management estimates that first quarter 2022 assay revenue will be between $3.4 million and $3.8 million, and full year 2022 assay revenue will be between $22 million and $26 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.39 USD | +6.53% | -21.92% | -77.71% |
05-14 | Earnings Flash (DMTK) DERMTECH Posts Q1 Revenue $3.8M | MT |
04-22 | North American Morning Briefing : Stock Futures -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-77.71% | 12.68M | |
-4.92% | 12.11B | |
-5.82% | 8.07B | |
+5.43% | 5.67B | |
+26.16% | 5.48B | |
-9.58% | 4.12B | |
-59.63% | 2.75B | |
+8.44% | 2.62B | |
-3.70% | 2.33B | |
+21.00% | 2.11B |
- Stock Market
- Equities
- DMTK Stock
- News DermTech, Inc.
- DermTech, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022